Agenda

• Welcome Back – First meeting since February 19, 2019
• Review ISP Task Force Charge
• Review of Medication & Pharmacy Domain Recommendations
  » Presented to HITAC March 19, 2019
• Discussion of Potential Additional Medication Sub-Domains
  » Adverse Drug Event data capture, reporting
  » FDA needs
  » Pharma/research needs
• Timeline and Work Plan
ISP Task Force Charge

- **Overarching Charge:** To make recommendations on priority uses of health information technology and the associated standards and implementation specifications that support such uses.

- **Specific Charge:** The ISP Task Force will:

  1. Make recommendations on the following:
     - Priority uses of health IT (consistent with the Cures Act’s identified priorities);
     - The standards and implementation specifications that best support or may need to be developed for each identified priority; and
     - Subsequent steps for industry and government action.

  2. Publish a report summarizing its findings.
Preview of Future Domains

Medication & Pharmacy Data
Sub-Domains

- Med dispense & administration data
- Discrete sigs
- PDMP data access and workflow integration
- Price transparency
- Prior authorization
- eRx forwarding
- Adverse Drug Event data
- Other FDA needs
- Pharma/research needs
Medication & Pharmacy Domain Preview

Priority 1

• Priority 1A: Medication administration/dispensation information is not universally available
• Priority 1B: Medication reconciliation at transitions of care is challenging
• Priority 1C: US Core FHIR profiles do not require transmittal of free-text sigs
• Priority 1D: Access to prescription drug monitoring program (PDMP) data can be cost prohibitive
• Priority 1E: It is difficult to know the net price of prescribed medications
• Priority 1F: Need standards to integrate Prior Authorization into prescribing workflows

Priority 2

• Priority 2A: National Library of Medicine RxNorm API does not return codes for discontinued drugs
• Priority 2B: Free text sigs are prevalent, but difficult to interpret/use when structured information is needed
• Priority 2C: There is currently not a way to "forward" an eRx to an alternate pharmacy
Potential New Sub-Domains

• Adverse Drug Event data
• Other FDA needs
• Pharma/research needs
## Timeline & Workplan

<table>
<thead>
<tr>
<th>Meeting Date</th>
<th>Draft Agenda Items</th>
</tr>
</thead>
</table>
| May 28       | • Brief Recap ISP TF recommendations to date  
               • Plan & Discuss Medication & Pharmacy Domains (sub-domains) |
| June 11      | • Price Transparency  
               • *Possible NCPDP & Surescripts Presentations* |
| June 25      | • Adverse Drug Events (ADE)  
               • *Possible FDA presentation* |
| July 9       | • Discuss & Draft Recommendations |
| July 23      | • Discuss & Draft Recommendations |
| August 13    | • Discuss & Draft Recommendations |
| August 27    | • Update and revise recommendations |
| September 10 | • Update and revise recommendations |
| September 17 | • HITAC Meeting  
               • *Present Draft of Recommendations at Sept 17 In-person Meeting* |
| October 16   | • HITAC Meeting  
               • *Present Final Recommendations at October 16 Virtual Meeting for Vote* |
To make a comment please call:

Dial: 1-877-407-7192

(once connected, press "*1" to speak)

All public comments will be limited to three minutes.

You may enter a comment in the “Public Comment” field below this presentation.

Or, email your public comment to onc-hitac@accelsolutionsllc.com.

Written comments will not be read at this time, but they will be delivered to members of the Workgroup and made part of the Public Record.
Questions
The Office of the National Coordinator for Health Information Technology

Health IT Advisory Committee

Meeting Adjourned